Development of an ELISA for the detection of 2-nitroimidazole hypoxia markers bound to tumor tissue.
Canine and rodent tumors covalently bind the fluorinated 2-nitroimidazole, CCI-103F, in a way that immunohistochemical analysis shows is consistent with the location of tumor hypoxia. We have now developed a rapid, quantitative, and non-radioactive enzyme linked immunosorbent assay for the binding of CCI-103F in biopsy samples of spontaneous canine tumors. Issues of antigen stability during tissue processing, calibration of the ELISA, and the use of biopsy samples for measuring tumor hypoxia by the ELISA approach are addressed.
Raleigh
J A
JA
Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill 27599.
Zeman
E M
EM
Rathman
M
M
LaDine
J K
JK
Cline
J M
JM
Thrall
D E
DE
D000818:Animals; D015687:Cell Hypoxia / Q000502:physiology*; D004285:Dogs; D004797:Enzyme-Linked Immunosorbent Assay; D008080:Liposarcoma / Q000503:physiopathology / Q000662:veterinary; D009369:Neoplasms / Q000503:physiopathology* / Q000662:veterinary; D009593:Nitroimidazoles / Q000378:metabolism; D013584:Sarcoma, Synovial / Q000503:physiopathology / Q000662:veterinary; D005466:Fluorocarbons
D009593:Nitroimidazoles; C049948:CCI 103F; D005466:Fluorocarbons